Aspire-Lakewood Holdings, Inc.
Sector: Pharmaceutical PreparationsCountry: USExchange: Nasdaq
DilutionScan read 27 of Aspire-Lakewood Holdings, Inc.'s SEC filings and found 3 warrant series, 6 convertibles, 2 equity lines, 5 S-1 registrations and 4 completed offerings on file for ASBP. Analysis updated Oct 21, 2026.
Signal8 Summary
ASBP
Distressed biotech pivoting to automotive
Snapshot
Aspire Biopharma is a tiny, cash-strapped biotech that is attempting a dramatic pivot into the automotive industry. The core biopharma business is effectively dormant, generating only $6K in revenue in FY 2025 while burning through $24.5M in net losses. The company has survived by issuing massive amounts of new shares, diluting existing holders by 116% in a single year, and executing two extreme reverse stock splits (1-for-40 and 1-for-30) to avoid delisting.
What's Happening Right Now
- : Aspire signed a definitive agreement to buy Dura Driver Control Systems, a major automotive supplier with $200M+ in revenue, for $30M in cash.
- : CEO Kraig Higginson issued a letter to shareholders describing 2026 as a defining year for the company's strategic transformation.
- : Aspire executed a 1-for-30 reverse stock split in May 2026, following a 1-for-40 split in January, to maintain Nasdaq listing compliance.
- : The board authorized a $5M share repurchase program, signaling confidence in its balance sheet despite recent financial distress.
- : The company closed the final tranche of a $21M private placement and secured a $22.5M credit facility to fund the acquisition.
